Valion Bio Closes $4.77M Series C Tranche — Only $1.5M Is New Cash
VBIO is trading near its 52-week low of $0.68 (12% above the low) on elevated volume (8.7× avg).
Summary
Valion Bio closed a $4.72M Series C preferred tranche and a $50,000 Series B tranche with 3i, but only $1.5M is new cash — the rest settles overdue true-up payments. The deal triggers price resets across its preferred and note stack and commits it to a drug-asset royalty agreement.
Key Events · Financing and Capital Events · VBIO
-
Series C Tranche Closes at $4.72M
Purchasers bought 4,717.73 Series C Preferred Shares and warrants for 2,524,343 common shares at a $1.0092 exercise price, for an aggregate purchase price of $4,717,717.61.
-
Only $1.5M Is New Cash
Of the purchase price, $3,217,717.61 is retained by purchasers to satisfy overdue cash true-up payments under Section 6(b) of the Series C Certificate of Designation; just $1,500,000 arrives as cash.
-
Price Resets Triggered Across Stack
The company must deliver notice of each price adjustment triggered by the closing under the Series B and Series C preferred, warrants, the $16,253,147.10 Note and the Note Warrant, including adjusted conversion/exercise prices and additional securities issuable.
-
Royalty and Registration Obligations
Within 30 days the company must sign a royalty agreement on its drug assets, and must file a resale registration statement within 30 days and have it effective within 60 days.
Analysis · VBIO · Life Sciences
Valion Bio has drawn another tranche from its existing 3i-led preferred facilities, but the headline $4.77M is mostly accounting: $3.22M is retained by the purchasers to settle overdue cash true-up payments, leaving just $1.5M of actual cash. Against a company that reported $2.1M in cash and going-concern doubt in its August 10-Q, that is barely more than a month of breathing room at the prior quarter's burn. The closing also triggers conversion and exercise price resets across the Series B and Series C preferred, warrants and the $16.25M senior secured note, and commits the company to a royalty agreement on its drug assets plus a resale registration statement within 30 days — both of which add future dilution and encumber assets. The $1.0092 warrant exercise price sits above today's $0.765 share price, so those warrants are out of the money at current levels.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 36.2% of the 898 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.75%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $0.68 to $72.73. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.